Dendrymery – fascynujące nanocząsteczki w zastosowaniu w medycynie

Kubiak, M.

Artykuł - szczegóły

Tytuł artykułu

Dendrymery – fascynujące nanocząsteczki w zastosowaniu w medycynie

Autorzy

Kubiak M.

Treść / Zawartość

Pełne teksty:

Pobierz

Identyfikatory

Warianty tytułu

Dendrimers – fascinating nanoparticles in the application in medicine

Języki publikacji

PL EN

Abstrakty

Dendrymery, to związki organiczne o regularnej strukturze, stanowiące stosunkowo nową klasę polimerów z potencjalnym zastosowaniem w wielu dziedzinach nauki oraz przemysłu. Cząsteczki te są symetrycznie rozgałęzione, przez co kształtem przypominają kulę. Dendrymery mogą znaleźć zastosowanie przede wszystkim w medycynie oraz nanotechnologii, a także w chemii organicznej i nieorganicznej.

Dendrimers are organic compounds with a regular structure. They are a relatively new class of polymers, which can find potential application in various fields of science and industry. Dendrimers are symmetrically branched, three-dimensional, mainly spherical molecules. Described nanoparticles can find potential application mainly in medicine, nanotechnology, and recently in inorganic and organic chemistry.

Słowa kluczowe

dendrymery nanocząsteczki w medycynie nanopolimery

dendrimer nanoparticles in medicinenanopolymers

Wydawca

Stowarzyszenie Inżynierów i Techników Przemysłu Chemicznego, ZW CHEMPRESS-SITPChem

Czasopismo

Chemik

Rocznik

2014

Tom

Vol. 68, nr 2

Strony

141--150

Opis fizyczny

Bibliogr. 41 poz., tab., rys.

Twórcy

autor

Kubiak M.

malgosia.m.kubiak@gmail.com

Studenckie Koło Naukowe Biotechnologów FER MENT , Wydział Biotechnologii i Nauk o Żywności, Politechnika Łódzka, Łódź

Bibliografia

1. Vögtle F., Weber E.: Octopus molecules. Angew. Chem. Int. Ed. 1974, 13, 12, 814–816.
2. Buhleier E., Wehner W., Vögtle F.: Cascade-chain-like and nonskidchain-like syntheses of molecular cavity topologies. Synthesis 1978, 2, 155–158.
3. Tomalia D.A., Baker H., Dewald J., Hall M., Kallos G., Martin S., Roeck J., Ryder J., Smith P.: A new class of polymers: starburst-dendritic macromolecules. Polym. J. 1985, 17, 1, 117–132
4. Tomalia D.A., Baker H., Dewald J., Hall M., Kallos G., Martin S., Roeck J., Ryder J., Smith P.: Dendritic macromolecules: synthesis of starburst dendrimers. Macromolecules 1986, 19, 9, 2466–2468
5. Newkome G.R., Yao Z., Baker G.R., Gupta V.K.: Cascade molecules:a new approach to micelles. A [27]-arborol. J. Org. Chem. 1985, 50, 11, 2003–2004
6. Urbańczyk-Lipkowska Z.: Dendrymery w naukach biomedycznych. Gaz Farm 2008, 11, 34–36
7. Hawker C.J., Frechet J.M.J.: Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J. Amer. Chem. Soc. 1990, 112, 21, 7638–7647
8. Doubrovin M., Serganova I., Mayer-Kuckuk P., Ponomares V., Blasberg R.G.: Multimodality in vivo molecular-genetic imaging. Bioconjugate Chem. 2004, 15, 6, 1376–1388
9. Caravan P., Ellison J.J., McMurry T.J, Lauffer R.B.: Gadolinium (III) chelates as MRI contrast agents: structure, dynamics and applications. Chem.Rev. 1999, 99, 9, 2293–2352
10. Tweedle M.F., Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest. Radiol. 1992, 27, S2-S6
11. Franano F.N., Edwards W.B., Welch M.J., Brechbiel M.W., Gansow O.A. Duncan J.R.: Biodistribution and metabolism of targeted and nontargeted protein-chelate-gadolinium complexes: evidence for gadolinium dissociation in vitro and in vivo. Magn. Reson. Imaging 1995, 13, 2, 201–214
12. Schuhmann-Giampieri G., Schmitt-Willich H., Frenzel T., Press W.R., Weinmann H.J.: In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. Invest. Radiol. 1991, 26, 11, 969–974
13. Wiener E.C., Brechbiel M.W., Brothers H., Magin R.L., Gansow O.A., Tomalia D.A., Lauterbur P.C.: Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn. Reson. Med. 1994, 31, 1, 1–8
14. Klajnert B., Bryszewska M.: Dendrimers in Medicine. Nova Science Publishers 2007, 19–35
15. Sękowski S., Miłowska K., Gabryelak T.: Dendrymery w naukach biomedycznych i nanotechnologii. Post. Hig. 2008, 62, 725–733
16. Klajnert B., Bryszewska M.: Dendrimers in Medicine. Nova Science Publishers 2007, 50–53
17. Roy R., Zanini D., Meunier S.J., Romanowska A.: Solid-phase synthesis of dendritic sialoside inhibitors of influenza A virus haemagglutinin. J. Chem. Soc., Chemical Communications 1993, 24, 1869–1872
18. Supattapone S., Nguyen H-O.B., Cohen F.E., Prusiner S.B., Scott M.R.: Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. USA 1999, 96, 25, 14529–14534
19. Klajnert B., Cortijo-Arellano M., Cladera J., Majoral J.P., Caminade A.M. , Bryszewska M.: Inﬂuence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185–208. Biochem. Biophys. Res. Commun. 2007, 364, 1, 20–25
20. Shaunak S., Thomas S., Gianasi E., Godwin A., Jones E., Teo I., Mireskandari K., Luthert P., Duncan R., Patterson S., Khaw P., Brocchini S. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol. 2004, 22, 8, 977–984
21. Caminade A.M., Turrin C.O., Majoral J.P.: Biological properties of phosphorus dendrimers. New J. Chem. 2010, 34, 8, 1512–1524
22. Turrin C. O., Caminade A. M., Majoral J. P., Poupot M., Fournie J. J.,Poupot R.: Immuno-modulations induced by phosphored dendrimers. Bull. Cancer. 2010, 97, S60-S61
23. Griffe L., Poupot M., Marchand P., Maraval A., Turrin C.O., Rolland O., Métivier P., Bacquet G., Fournié J.J., Caminade A.M., Poupot R., Majoral J.P.: Multiplication of human natural killer cells by nanosized phosphonatecapped dendrimers. Angew. Chem. Int. Ed. 2007, 46, 14, 2523–2526
24. Chauhan A.S., Diwan P.V., Jain N.K., Tomalia D.A.: Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly-(amidoamine) dendrimers. Biomacromolecules 2009, 10, 5, 1195–1202
25. Milhem O.M., Myles C., McKeown N.B., Attwood D., D’Emanuele A.: Polyamidoamine Starburst dendrimers as solubility enhancers. Int. J. Pharm. 2000, 197, 239–241
26. Devarakonda B., Hill R.A., Liebenberg W., Brits M., de Villiers M.M.: Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int. J. Pharm. 2005, 304, 193–209
27. Malik N., Evagorou E.G., Duncan R.: Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999, 10, 8, 767–776
28. Majoros I.J., Thomas T.P., Mehta C.B., Baker J.R. Jr: Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem. 2005, 48, 19, 5892–5899
29. Na M., Yiyun C., Tongwen X., Yang D., Xiaomin W., Zhenwei L., Zhichao C., Guanyi H., Yunyu S., Longping W.: Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur. J. Med. Chem. 2006, 41, 5, 670–674
30. Bielinska A., Kukowska-Latallo J.F., Johnson J., Tomalia D.A., Baker J.R. Jr.: Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 1996; 24, 11, 2176–2182
31. Dufes C., Keith W.M., Proutski I., Bilsland A., Uchegbu I.F., Schätzlein A.G.: Synergistic anti-cancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res. 2005, 65, 18, 8079–8084
32. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., Tomalia D.A., Baker J.R. Jr.: Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U S A 1996, 93, 4897–4902
33. Qin L., Pahud D.R., Ding Y., Bielinska A.U., Kukowska-Latallo J.F., Baker J.R.Jr., Bromberg J.S.: Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Hum. Gene. Ther. 1998, 9, 4, 553–560
34. Sato N., Kobayashi H., Saga T., Nakamoto Y., Ishimori T., Togashi K., Fujibayashi Y., Konishi J., Brechbiel M.W.: Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. 2001, 7, 11, 3606–3612
35. Uchida E., Mizuguchi H., Ishii-Watabe A., Hayakawa T.: Comparison of the efficiency and safety of non-viral vector-mediated gene transfer intoa wide range of human cells. Biol. Pharm. Bull.2002, 25, 7, 891–897
36. Leng Q., Mixson A.J.: Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection. Nucleic Acids Res. 2005, 33, 4, e40
37. Dzmitruk V., Shcharbin D., Pedziwiatr E., Bryszewska M.: Dendrimers in Anti-HIV Therapy. Advances in Nanocomposite Technology 2011
38. Boas U., Heegaard P.M.: Dendrimers in drug research. Chem. Soc. Rev. 2004, 33,1, 43–63
39. Chen C.Z., Cooper S.L.: Interactions between dendrimer biocides and bacterial membranes. Biomaterials 2002, 23, 16, 3359–3368
40. Price C.F,, Tyssen D., Sonza S., Davie A., Evans S., Lewis G.R., Xia S., Spelman T., Hodsman P., Moench T.R., Humberstone A., Paull J.R., Tachedjian G.: SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLOS One2011, 6, 9, e24095
41. Klajnert B., Cortijo-Arellano M., Cladera J., Bryszewska M.: Influence of dendrimer’s structure on its activity against amyloid fibril formation. Biochem. Biophys. Res. Commun. 2006, 345, 1, 21-28

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-72c5d292-2398-4fdf-835c-ca202ca05638